Humacyte Submits Marketing Authorization Application for Symvess® in Israel for Vascular Trauma Repair

Rhea-AI Summary

Humacyte (Nasdaq: HUMA) submitted a Marketing Authorization Application (MAA) to the Israel Ministry of Health for Symvess, its acellular tissue engineered vessel for extremity arterial trauma repair, on March 17, 2026.

Humacyte is also pursuing hospital-by-hospital access in Israel before approval and plans broader Middle East expansion; clinical data cited include a retrospective 16-patient wartime series with 100% survival, zero amputations and zero conduit infections.

Positive

• MAA submission filed with Israel Ministry of Health (March 17, 2026)
• FDA approval supported by Phase 2/3 U.S. and Israel trial
• Retrospective wartime series: 16 patients with 100% survival and zero amputations
• Off-the-shelf availability designed to save critical surgical time

Negative

• Boxed warning for graft failure with risk of life-threatening hemorrhage
• Anastomotic failure reported within 36 days post-implantation in trials
• Thrombosis and graft thrombosis noted as common adverse reactions (≥10%)
• Contraindicated if patient cannot receive long-term antiplatelet therapy

Key Figures

Patients in study: 16 patients Survival rate: 100% survival Amputation rate: 0 amputations +3 more

6 metrics

Patients in study 16 patients Retrospective battlefield program in Ukraine

Survival rate 100% survival 16-patient retrospective wartime injury study

Amputation rate 0 amputations 16-patient retrospective wartime injury study

Conduit infections 0 conduit infections 16-patient retrospective wartime injury study

Anastomotic failure window first 36 days Timeframe when anastomotic failures occurred post-implantation

Adverse reaction threshold ≥ 10% Frequency defining common adverse reactions for Symvess

Market Reality Check

Price: $1.12 Vol: Volume 4,216,306 is in li...

normal vol

$1.12 Last Close

Volume Volume 4,216,306 is in line with 20-day average 4,322,470 (relative 0.98x). normal

Technical Price 1.12 is trading below 200-day MA of 1.62 and 66.67% below 52-week high.

Peers on Argus

HUMA was down 3.45% while peers were mixed: IMMP down 5.04%, SLN down 2.0%, EDIT...

1 Up 1 Down

HUMA was down 3.45% while peers were mixed: IMMP down 5.04%, SLN down 2.0%, EDIT up 3.25%, OABI up 1.67%, VOR roughly flat. Mixed peer action and scanner flags for both up (SLN) and down (IMMP) names point to a stock-specific move.

Historical Context

5 past events · Latest: Mar 02 (Neutral)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Mar 02	Investor conferences	Neutral	+0.5%	Management scheduled March healthcare conference presentations and webcasts.
Feb 18	Clinical data update	Positive	-5.3%	36‑month V005 trial showed strong infection-free and limb-salvage outcomes.
Feb 09	DoD funding news	Positive	+30.0%	U.S. DoD appropriations supported procurement of biologic vascular repair tech.
Jan 08	Health economics data	Positive	-2.5%	Five‑year analysis showed high costs of complications and highlighted Symvess benefits.
Jan 05	Israel MAA plan	Positive	+8.7%	Company outlined Q1 2026 plan to file Israel MAA for Symvess.

Pattern Detected

News with clear positive fundamentals (DoD funding, Israel MAA plans) often saw strong or moderate gains, while positive clinical/safety updates have twice been followed by selloffs, indicating a tendency to fade good data-focused news.

Recent Company History

Over the past few months, Humacyte has advanced Symvess with multiple updates. A planned Israel MAA in Q1 2026 on Jan 5 coincided with a +8.72% move, while new U.S. DoD funding on Feb 9 saw a strong +30.02% reaction. By contrast, positive long-term Symvess data on Feb 18 was followed by a -5.26% drop. Today’s actual MAA submission in Israel continues this regulatory expansion theme.

Market Pulse Summary

This announcement advances Symvess’s global reach via a Marketing Authorization Application in Israe...

Analysis

This announcement advances Symvess’s global reach via a Marketing Authorization Application in Israel and potential pre-approval access, building on FDA approval and prior clinical data, including a 16-patient wartime study with 100% survival. Historical news shows the stock reacting more to funding and market-access catalysts than to data alone. Investors may watch future regulatory decisions, commercialization uptake, and safety outcomes given the graft-failure boxed warning.

Key Terms

marketing authorization application, acellular tissue engineered vessel, anastomotic failure, thrombosis, +3 more

7 terms

marketing authorization application regulatory

"announced that it submitted a Marketing Authorization Application (MAA) with the Israel Ministry"

A marketing authorization application is a formal request submitted to a government regulator asking permission to sell a prescription medicine or medical product in a country or region. Think of it like asking for a business license after showing evidence the product is safe and works; investors care because approval determines whether the product can generate sales, how soon revenue starts, and how much regulatory risk and uncertainty remains.

acellular tissue engineered vessel medical

"for approval of the acellular tissue engineered vessel (ATEV, or Symvess) for arterial trauma repair"

Acellular tissue engineered vessels are lab-made replacement blood vessels created from biological materials but manufactured without living cells, so they act like a ready-made tube that the body can grow into and line with its own cells. For investors, they matter because they target a steady medical need (for example, replacing or bypassing damaged vessels) and carry commercial upside if proven safe and long-lasting, while also involving manufacturing, clinical trial and regulatory risks.

anastomotic failure medical

"Anastomotic failure has occurred in patients treated with Symvess"

Anastomotic failure is when a surgical connection between two bodily structures—most often sections of intestine—is unable to hold and leaks, separates, or closes. For investors, it matters because such failures can increase patient complications, lengthen hospital stays, raise treatment costs, trigger product recalls or lawsuits, and slow or block regulatory approvals and market adoption of surgical devices, materials, or therapies designed to create or protect these joins.

thrombosis medical

"Thrombosis has occurred in patients treated with Symvess"

Thrombosis is the formation of a blood clot inside a blood vessel that can block normal blood flow, like a plaster clogging a pipe. It matters to investors because clotting events affect the safety profile and regulatory review of drugs, medical devices and treatments, can drive costly litigation or recalls, and influence healthcare demand and company valuations tied to patient outcomes and product approvals.

antiplatelet therapy medical

"patients received antiplatelet therapy following implantation of Symvess to reduce the risk"

Antiplatelet therapy uses medicines that make blood platelets less likely to stick together, lowering the chance blood clots will form. Think of platelets as tiny workers or glue patches that seal leaks in blood vessels; these drugs reduce that “glue” to prevent heart attacks, strokes, or clots on medical devices. For investors this matters because safety, trial results, approvals, and prescribing patterns directly affect demand, market size, and regulatory risk for related drugs and devices.

variant creutzfeldt-jakob disease medical

"prion protein that causes bovine spongiform encephalopathy and the cause of a rare fatal condition in humans called variant Creutzfeldt-Jakob disease"

A fatal, rare brain disorder caused by misfolded proteins that progressively destroy brain tissue and function; it develops after exposure to those abnormal proteins and leads to rapidly worsening mental and physical decline. Investors should care because outbreaks or confirmed cases can trigger regulatory action, product recalls, legal liabilities, and shifts in consumer confidence that affect food producers, healthcare providers, insurers, and related industries—similar to how a safety scare can sink demand and raise costs.

pyrexia medical

"The most common adverse reactions (occurring at ≥ 10%), were vascular graft thrombosis, pyrexia (fever) and pain"

Pyrexia is the medical term for a fever—an elevated body temperature that signals the body is fighting infection, inflammation, or reacting to a medication. For investors, pyrexia matters because it is a common safety signal in clinical trials and product use that can delay approvals, trigger additional testing, or affect workforce health and production; think of it as a warning light that prompts further investigation into a drug or operation.

AI-generated analysis. Not financial advice.

- Humacyte is also pursuing a mechanism for making Symvess available in Israel on a hospital-by-hospital basis in advance of MAA approval - 

- Preparation is underway for expansion of Symvess into other countries, including in the Middle East -

DURHAM, N.C., March 17, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced that it submitted a Marketing Authorization Application (MAA) with the Israel Ministry of Health for approval of the acellular tissue engineered vessel (ATEV, or Symvess) for arterial trauma repair. In response to surgeon request, Humacyte is also pursuing a mechanism for making Symvess available in Israel on a hospital-by-hospital basis in advance of MAA approval.

“Surgeons, hospitals and patients in Israel have made an important contribution to the development of Symvess, and we are pleased to have taken an important step to gaining potential approval in this country,” said Laura Niklason, M.D., Ph.D., Founder and Chief Executive Officer of Humacyte. “The MAA submission represents just the first step in our planned global expansion of Symvess as we expect that our FDA approval and strong body of clinical results provide opportunities for expedited commercialization pathways in multiple countries, including others in the Middle East.”

Vascular trauma wounds are challenging for surgeons to treat, and autologous vein grafts have traditionally served as the standard of care due to their durability and low infection rates. However, autologous grafts are not always feasible in trauma settings where veins are damaged or there is little time to harvest vein. Symvess is designed to be immediately available off-the-shelf — saving critical surgical time in emergency situations — and has also consistently demonstrated low rates of infection and high rates of limb salvage. In addition to a civilian Phase 2/3 trial conducted in the U.S. and Israel which supported the FDA approval Symvess, the product was evaluated on the battlefield in Ukraine, where patients with gunshots, shrapnel, blasts, and accidents were treated as part of a humanitarian program. Sixteen patients from this program followed in a retrospective, observational study had 100% survival, zero amputations and zero conduit infections despite incurring serious wartime injuries.

For uses other than the FDA approval in the extremity vascular trauma indication, Symvess is an investigational product and has not been approved for sale by the FDA or any other regulatory agency.

INDICATION

Symvess is an acellular tissue engineered vessel indicated for use in adults as a vascular conduit for extremity arterial injury when urgent revascularization is needed to avoid imminent limb loss, and autologous vein graft is not feasible.

IMPORTANT SAFETY INFORMATION

BOXED WARNING: GRAFT FAILURE

Loss of Symvess integrity due to mid-graft rupture or anastomotic failure can result in life threatening hemorrhage.

CONTRAINDICATIONS

DO NOT use Symvess in patients who have a medical condition that would preclude long-term antiplatelet therapy (such as aspirin or clopidogrel) after resolution of acute injuries. 

WARNINGS AND PRECAUTIONS

• Graft Rupture
  

Vascular graft rupture has occurred in patients treated with Symvess. Advise patients that arterial bleeding can be life-threatening and to seek emergent medical evaluation for any signs or symptoms of graft rupture such as bleeding, pain and swelling in the extremity, or signs of extremity ischemia.

• Anastomotic Failure
  

Anastomotic failure has occurred in patients treated with Symvess. In clinical studies of Symvess, anastomotic failure occurred within the first 36 days post-implantation. Monitor patients for signs of anastomotic failure such as pain and swelling at the surgical site, decreasing hemoglobin or other signs and symptoms of bleeding. Advise patients to seek urgent medical evaluation if they have any signs or symptoms that may be indicative of anastomotic failure such as bleeding, swelling or worsening pain at the surgical site or changes in color of overlying skin.

• Thrombosis
  

Thrombosis has occurred in patients treated with Symvess. In clinical trials of Symvess, patients received antiplatelet therapy following implantation of Symvess to reduce the risk of thrombosis. The risk of thrombosis may increase in patients who discontinue antiplatelet therapy. Anti-platelet therapy is recommended following treatment with Symvess.

• Transmission of Infectious Diseases
  

Symvess is manufactured using cells and reagents that may transmit infectious diseases or infectious agents. The cells used in the manufacture of Symvess are derived from a donor who met the donor eligibility requirements for transmissible infectious diseases which includes screening and testing of risks associated with human immunodeficiency virus 1 (HIV-1), human immunodeficiency virus 2 (HIV-2), hepatitis B virus (HBV), hepatitis C virus (HCV), and syphilis (Treponema pallidum). The cell banks are tested negative for human and animal viruses, retroviruses, bacteria, fungi, yeast, and mycoplasma. While all animal-derived reagents are tested for animal viruses, bacteria, fungi, and mycoplasma before use, these measures do not eliminate the risk of transmitting these or other transmissible infectious diseases and disease agents. Fetal bovine serum is sourced to minimize the risk of transmitting a prion protein that causes bovine spongiform encephalopathy and the cause of a rare fatal condition in humans called variant Creutzfeldt-Jakob disease. No transmissible agent infections have been reported during clinical testing.

ADVERSE REACTIONS

The most common adverse reactions (occurring at ≥ 10%), were vascular graft thrombosis, pyrexia (fever) and pain.

Please see full Prescribing Information at www.symvess.com, including Boxed Warning, for Symvess.

About Humacyte

Humacyte, Inc. (Nasdaq: HUMA) is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues, advanced tissue constructs, and organ systems designed to improve the lives of patients and transform the practice of medicine. The Company develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Humacyte’s Biologics License Application for the acellular tissue engineered vessel (ATEV) in the vascular trauma indication was approved by the FDA in December 2024. ATEVs are also currently in late-stage clinical trials targeting other vascular applications, including arteriovenous (AV) access for hemodialysis and peripheral artery disease (PAD). Preclinical development is also underway in coronary artery bypass grafts, pediatric heart surgery, treatment of type 1 diabetes, and multiple novel cell and tissue applications. Humacyte’s 6mm ATEV for AV access in hemodialysis was the first product candidate to receive the FDA’s Regenerative Medicine Advanced Therapy (RMAT) designation and has also received FDA Fast Track designation. Humacyte’s 6mm ATEV for urgent arterial repair following extremity vascular trauma and for advanced PAD also have received RMAT designations. The ATEV received priority designation for the treatment of vascular trauma by the U.S. Secretary of Defense. For more information, visit www.Humacyte.com.

Forward-Looking Statements

This press release contains forward-looking statements that are based on beliefs and assumptions and on information currently available. In some cases, you can identify forward-looking statements by the following words: “may,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “ongoing” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties, and other factors that may cause actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. Although we believe that we have a reasonable basis for each forward-looking statement contained in this press release, we caution you that these statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot be certain. Forward-looking statements in this press release include, but are not limited to, our plans and ability to commercialize Symvess and, if approved by regulatory authorities, our product candidates, successfully and on our anticipated timelines; the degree of market acceptance of and the availability of third-party coverage and reimbursement for Symvess and, if approved by regulatory authorities, our product candidates; our ability to manufacture Symvess and, if approved by regulatory authorities, our product candidates in sufficient quantities to satisfy our clinical trial and commercial needs; the anticipated benefits of our ATEVs relative to existing alternatives; our plans and ability to execute product development, process development and preclinical development efforts successfully and on our anticipated timelines; our ability to design, initiate and successfully complete clinical trials and other studies for our product candidates and our plans and expectations regarding our ongoing or planned clinical trials; the anticipated characteristics and performance of our ATEVs; the implementation of our business model and strategic plans for our business; our ability to execute and achieve the expected benefits of our cost-saving measures and whether our efforts will result in further actions or additional asset impairment charges that adversely affect our business; and the timing or likelihood of regulatory filings, acceptances and approvals. We cannot assure you that the forward-looking statements in this press release will prove to be accurate. These forward-looking statements are subject to a number of significant risks and uncertainties that could cause actual results to differ materially from expected results, including, among others, changes in applicable laws or regulations, the possibility that Humacyte may be adversely affected by other economic, business, competitive and/or reputational factors, and other risks and uncertainties, including those described under the header “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2024 and Form 10-Q for the quarter ended September 30, 2025, each filed by Humacyte with the SEC, and in future SEC filings. Most of these factors are outside of Humacyte’s control and are difficult to predict. Furthermore, if the forward-looking statements prove to be inaccurate, the inaccuracy may be material. In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by us or any other person that we will achieve our objectives and plans in any specified time frame, or at all. Except as required by law, we have no current intention of updating any of the forward-looking statements in this press release. You should, therefore, not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this press release.

Humacyte Investor Contact:
Joyce Allaire
LifeSci Advisors LLC
+1-617-435-6602
jallaire@lifesciadvisors.com
investors@humacyte.com

Humacyte Media Contact:
Rich Luchette
Precision Strategies
+1-202-845-3924
rich@precisionstrategies.com
media@humacyte.com

FAQ

What did Humacyte (HUMA) file with Israeli regulators on March 17, 2026?

Humacyte filed a Marketing Authorization Application (MAA) for Symvess in Israel. According to Humacyte, the MAA seeks approval of Symvess as an off-the-shelf vascular conduit for urgent extremity arterial injuries when autologous vein grafts are not feasible.

Will Symvess be available in Israel before formal approval for HUMA shareholders?

Humacyte is pursuing hospital-by-hospital access in Israel in advance of MAA approval. According to Humacyte, this mechanism responds to surgeon requests and aims to enable earlier clinical use at individual hospitals pending regulatory clearance.

What clinical evidence supports Symvess for extremity vascular trauma (HUMA)?

Clinical evidence includes a Phase 2/3 trial in the U.S. and Israel and a retrospective wartime study. According to Humacyte, 16 battlefield patients had 100% survival, zero amputations and zero conduit infections in that observational series.

What are the main safety concerns for Symvess that HUMA investors should know?

Key safety issues include graft rupture, anastomotic failure and thrombosis, which can be life-threatening. According to Humacyte, graft failure risks include mid-graft rupture causing hemorrhage and anastomotic failures occurring within the first 36 days.

How does Symvess aim to benefit surgeons and emergency patients (HUMA)?

Symvess is designed as an immediately available off-the-shelf vascular conduit to save surgical time in emergencies. According to Humacyte, it addresses situations where autologous vein grafts are not feasible due to injury or time constraints.